News

In zebrafish, a way to find new cancer therapies, targeting tumor promoters

Vector reports on a new study that finds that retinoic acid, best known as an acne treatment, may also be effective in treating adenoid cystic carcinoma.

Leslie Kean, MD, PhD, joins Dana-Farber/Boston Children's Stem Cell Transplantation program

Kean will assume overall leadership in the program’s clinical practice and research in coordination with the Clinical Director, Leslie Lehmann, MD.

Dana-Farber/Boston Children's again ranked among the top national pediatric cancer programs

U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #3 in the nation in its new 2018-19 Best Children's Hospitals report.

Solving the DIPG puzzle a single cell at a time

Vector reports that scientists have discovered that DIPG/DMG tumors are made up of H3K27M-mutated cell populations that contain many cells stuck in a stem-cell-like state, fueling tumor growth.

Probing the brain’s earliest development, with a detour into rare childhood cancers

In this Vector report, researchers from Boston Children's Hospital found that gaining a greater understanding of how the c-Myc gene functions could lead to new discoveries in neurodevelopment and pediatric cancers.

Pioneering hematologist to receive 2018 Nemmers Prize in Medical Science

Stuart H. Orkin, MD, an investigator of the Howard Hughes Medical Institute at Boston Children’s Hospital and Dana-Farber Cancer Institute and professor at Harvard Medical School known for his landmark discoveries into blood cell development and the genetic basis of blood disorders, is the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University.

A bold strategy to enhance CAR T-cell therapies, capable of targeting DIPG and other tough-to-treat cancers

As reported in Vector, a Boston-based team of researchers, made up of scientists and pediatric oncologists, believe a better CAR T-cell therapy is on the horizon.

Dana-Farber/Boston Children’s researcher is part of a new Stand Up To Cancer campaign with Marvel Studios’ Avengers and American Airlines

Today, Stand Up To Cancer (SU2C), American Airlines and Marvel Studios’ Avengers: Infinity War announced a powerful collaboration as they team up in the fight against cancer.

Zeroing in on the fetal-to-adult hemoglobin switch and a new way to combat sickle cell disease

In this Vector report, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reveal how the protein, BCL11A, controls the switch in the body’s production of fetal hemoglobin to adult hemoglobin.

A breakthrough in our understanding of how red blood cells develop

In this Vector report, scientists make a new discovery about what drives the development of mature red blood cells after taking a deep dive into the molecular underpinnings of Diamond-Blackfan anemia.